| Identification | More | [Name]
[4-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2,5-dioxabi cyclo[4.4.0]deca-6,8,10-trien-4-yl)methanone | [CAS]
74191-85-8 | [Synonyms]
[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2,5-dioxabi cyclo[4.4.0]deca-6,8,10-trien-4-yl)methanone
DOXAZOSIN
DoxazosinMesylate77883-43-3/Base
DOXAZOSIN(SUBJECTTOPATENTFREE)
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-
UK 33,274
UK 33274
[4-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2,5-dioxabi cyclo[4.4.0]deca-6,8,10-trien-4-yl)methanone
DOXAZOSINMESYTL
4-Amino-2-[4-(1，4-benzodioxan-2-carbonyl)piperazin-1-y1]-6，7-dimethoxy quinazoline
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine
1-(4-Amino-6,7-dimethoxyquinazolin-2-yl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine
6,7-Dimethoxy-2-[4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-1-piperazinyl]quinazoline-4-amine | [EINECS(EC#)]
616-059-6 | [Molecular Formula]
C23H25N5O5 | [MDL Number]
MFCD00800482 | [Molecular Weight]
451.48 | [MOL File]
74191-85-8.mol |
| Hazard Information | Back Directory | [Description]
Doxazosin mesylate is a selective alpha, blocker indicated for the treatment of
hypertension, reportedly of special benefit as a first-line agent in the most hypertonic
patient population. Another advantage of doxazosin is its favorable effect on blood lipids;
it significantly increases the HDL/total cholesterol ratio and decreases the total cholesterol
as well as triglycerides levels. | [Originator]
Pfizer (United Kingdom) | [Uses]
ACIPHEX therapeutic Erosive or Ulcerative Gastroesophageal Reflux Disease | [Definition]
ChEBI: A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl
roup at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure. | [Brand name]
Cardura (Pfizer);Carduran. | [General Description]
Doxazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazine(Cardura), is a quinazoline compound that selectively inhibitsthe α1-subtype of α-adrenergic receptors. This agentis very useful in the management of hypertension associatedwith pheochromocytoma. | [Clinical Use]
Alpha-adrenoceptor blocker:
Hypertension
Benign prostatic hyperplasia (BPH) | [Drug interactions]
Potentially hazardous interactions with other drugs
Antidepressants: enhanced hypotensive effect with
MAOIs.
Avanafil, vardenafil, sildenafil and tadalafil: enhanced
hypotensive effect, avoid with tadalafil, start the
others at the lowest possible dose.
Beta-blockers: enhanced hypotensive effect;
increased risk of first dose hypotensive effect.
Calcium-channel blockers: enhanced hypotensive
effect, increased risk of first dose hypotensive effect.
Diuretics: enhanced hypotensive effect, increased risk
of first dose hypotensive effect.
Moxisylyte: possibly severe postural hypotension
when used in combination. | [Metabolism]
Doxazosin is extensively metabolised in the liver,
and excreted in faeces as inactive metabolites
(6-hydroxydoxazosin) and a small amount of unchanged
drug |
|
|